Therapy News and Research

RSS

Research focuses on JQ1 molecule that tricks NUT midline carcinoma cancer cells

NUT midline carcinoma (NMC) is a cancer without a cure, and one that affects all age groups. NMC is a rapid-growth disease with an average survival time of four and a half months after diagnosis, making the development of clinical trials for potential therapies or cures for this cancer difficult, to say the least.

29 Oct 2011

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.

29 Oct 2011

NYUCN to study 'Test and Linkage to Care Among Injecting Drug Users Kenya'

New York University College of Nursing (NYUCN) received a five-year, $4,161,665.00 grant from the National Institute of Health's National Institute on Drug Abuse (NIH/NIDA) to research "Test and Linkage to Care Among Injecting Drug Users (TLC_IDU) Kenya."

29 Oct 2011

More than 50,000 patients at high risk of SCA have been prescribed ZOLL's LifeVest

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that more than 50,000 patients at high risk of sudden cardiac arrest (SCA) have been prescribed the LifeVest Wearable Defibrillator.

29 Oct 2011

FDA approves Medtronic's LGS IDE for clinical trial to treat Type 1 diabetes

In our continued commitment to develop an artificial pancreas, Medtronic, Inc. today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal in-home clinical trial protocol for the ASPIRE study of the MiniMed Paradigm System featuring Low Glucose Suspend (LGS) automation.

From Medtronic 29 Oct 2011

Sorin Group third quarter revenues decrease 2.1% to €171.4 million

Sorin Group: Revenues of €171.4 million, a 2.1% decline (-4.9% as reported) over the same period last year.

29 Oct 2011

BZL and ATLAB Pharma partner to develop 177Lu-J591 for metastatic prostate cancer treatment

ATLAB Pharma SAS and BZL Biologics LLC have entered into a sublicense agreement to develop 177Lu-J591 for cancer treatment. It includes exclusive rights to manufacture, develop and commercialize this radiopharmaceutical product worldwide as well as a joint Phase IIB/III clinical validation program.

29 Oct 2011

Spherix closes private placement transaction

Spherix Incorporated – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today announced the closing of previously announced agreements to sell $1.25 million of shares of its common stock together with warrants to purchase additional shares of its common stock in a private placement transaction.

29 Oct 2011

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

Eli Lilly and Company announced today that the European Commission has granted approval for the use of ALIMTA (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer, called advanced nonsquamous non-small cell lung cancer

29 Oct 2011

New drug could combat cardiovascular disease

A new therapy being studied in non-human primates by researchers at Wake Forest Baptist Medical Center and colleagues is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.

29 Oct 2011

Varian to supply TrueBeam treatment systems to Lund University Hospital

Varian Medical Systems has been awarded a contract to supply four TrueBeam treatment systems to Lund University Hospital in Sweden, one of the country's largest radiotherapy departments. The order, confirmed in September, is aimed at cutting treatment waiting lists in the Skane region of Sweden and includes an option to acquire two further TrueBeam systems in 2014.

28 Oct 2011

Platform approach to chemically incorporate homing receptors onto surface of cells

Stem cell therapies hold enormous potential to address some of the most tragic illnesses, diseases, and tissue defects world-wide. However, the inability to target cells to tissues of interest poses a significant barrier to effective cell therapy.

28 Oct 2011

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its third quarter 2011 results.

28 Oct 2011

Researchers explore novel therapeutic approach for thyroid cancer

Some forms of differentiated thyroid cancer (DTC) respond to treatment with radioactive iodine, which is taken up by the thyroid gland, destroying the cancerous cells. However patients with two forms of thyroid cancer, radioiodine-refractory DTC and anaplastic thyroid cancer (ATC), do not benefit from radioiodine therapy, and other treatment options are limited.

28 Oct 2011

Novel technique saves Gulf War veteran's forearm

A plastic surgeon at UT Southwestern Medical Center recently used a novel technique to save the arm of a Gulf War veteran who was rushed to Parkland Memorial Hospital after a horrific accident.

28 Oct 2011

Fasudil drug shows promise against cerebral cavernous malformation

A drug treatment has been proven to prevent lesions from cerebral cavernous malformation — a brain blood vessel abnormality that can cause bleeding, epilepsy and stroke — for the first time in a new study.

28 Oct 2011

RA drug reduces kidney cyst growth in ADPKD mouse model

Scientists at UC Santa Barbara have discovered that patients with an inherited kidney disease may be helped by a drug that is currently available for other uses.

28 Oct 2011

Nestin-driven oncolytic viruses show effectiveness in glioblastoma models

A new fourth-generation oncolytic virus designed to both kill cancer cells and inhibit blood-vessel growth has shown greater effectiveness than earlier versions when tested in animal models of human brain cancer.

28 Oct 2011

Lenvatinib may achieve partial response in thyroid, endometrial, and renal cancers

Phase 1 clinical studies of the experimental anticancer drug lenvatinib indicate that it may achieve at least a partial response in thyroid, endometrial, and renal cancers and melanoma.

28 Oct 2011

CINJ experts available to discuss risk factors of pancreatic cancer

According to the American Cancer Society, pancreatic cancer is the fifth leading cancer killer in the country, with nearly 44,000 new cases expected in 2011 and more than 37,600 deaths by year's end. In New Jersey alone, an estimated 1,100 deaths are predicted this year due to the disease. The death of Steve Jobs, who suffered from a form of pancreatic cancer, has brought increased attention to the disease in recent weeks.

28 Oct 2011